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 PLAIN LANGUAGE SUMMARY 
 
 
Key message: In 2008, legal measures were introduced to manage the misuse of 
medicines containing pseudoephedrine or ephedrine. A review of evidence conducted 
in 2011 shows that the measures are continuing adequately to manage the misuse of 
these medicines. 
 
 
Background 
 
The Medicines and Healthcare products Regulatory Agency (MHRA) is the government 
agency responsible for regulating medicines and medical devices in the UK. We 
continually review the safety of medicines and vaccines in the UK, and inform 
healthcare professionals and the public of the latest updates through several means, 
including public assessment reports.  
 
The following report presents the 2011 review of the impact of measures introduced to 
control the potential misuse of medicines containing pseudoephedrine (PSE), or 
ephedrine (EPH), in the manufacture of the Class A controlled drug 
methylamphetamine. These measures were introduced in 2007–2008, and their impact 
has been reviewed yearly. 
 
PSE and EPH are nasal decongestantsa contained in many cough and cold medicines 
sold over-the-counter (OTC) in UK pharmacies. There is concern that PSE and EPH 
can be extracted from these medicines and used in the illegal manufacture of the Class 
A controlled drug methylamphetamineb – a highly addictive drug which affects the 
central nervous system and can cause serious physical and psychological harm. This 
concern prompted a public consultation in 2007, following which the Commission on 
Human Medicinesc (CHM) advised that a number of measures should be introduced to 
control the supply of OTC medicines containing PSE and EPH. These measures 
included reducing the pack size for OTC products containing PSE and EPH, and a 
restriction on sale to one pack per transaction. 
 
The CHM also advised that a Working Group should be set up to monitor the 
effectiveness of the pharmacy controls, and to advise the CHM on other measures that 
could be put in place to minimise the misuse of OTC medicines containing PSE or 
EPH. The Working Group was established in September 2007. Based on 
recommendations from CHM, legal sales restrictions were put in place on April 1st 2008 
which made it illegal to sell or supply: 
 
• any product that contains more than 720 mg PSE or 180 mg EPH without a 
prescription  
• a combination of products that between them add up to more than 720 mg PSE 
or 180 mg EPH without a prescription 
• a product that contains PSE and a product that contains EPH in one transaction 
 
In addition, the Royal Pharmaceutical Society (RPS), formerly known as the Royal 
Pharmaceutical Society of Great Britain, issued guidance that the sale and supply of 
products containing PSE or EPH must only be carried out by pharmacists or suitably 
trained pharmacy staff under the supervision of a pharmacist. 
 
                                                 
a Drugs which help to clear a blocked nose 
b Commonly known as ‘methamphetamine’, ‘crystal meth’ or ‘ice’ 
c An independent body which gives advice to government Ministers about the safety, quality, and efficacy 
of medicines 
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Impact of restrictions and CHM recommendations 
 
In 2009 and 2010, the CHM reviewed the evidence of the impact of these measures to 
control the misuse of PSE or EPH-containing medicines. Two public assessment 
reports giving full details of the evidence, and the CHM’s conclusions are available on 
our website: MHRA Public Assessment Report: Controlling the risk of misuse of 
medicines containing pseudoephedrine and ephedrine, and MHRA Public Assessment 
Report: Pseudoephedrine and ephedrine: managing the risk of misuse of medicines – 
July 2010 update. The evidence presented in these reports showed that the measures 
were helping to contain the potential problem of misuse, and that the sale of PSE and 
EPH products had reduced.  
 
Stakeholders including the pharmacy profession, the General Pharmaceutical Council 
(GPhC)a, the Home Office, the Association of Chief Police Officers (ACPO) and the 
Serious Organised Crime Agency (SOCA) have continued to take measures to 
minimise the misuse of medicines containing PSE and EPH. They report that these 
measures are continuing to be successful, and, for our 2011 review, have recently 
provided updated information on the impact of these measures, such as: 
 
• The RPS, the Pharmaceutical Society of Northern Ireland (PSNI), the National 
Pharmacy Association (NPA), the Company Chemists Association (CCA) and 
the Proprietary Association of Great Britain (PAGB) continue to raise and 
maintain awareness in the pharmacy profession of the indirect abuse potential 
of medicines containing PSE or EPH. 
 
• In a survey conducted in June 2011 of 410 NPA members, 97% were aware of 
the rules regarding sales of PSE. This level of awareness is unchanged from 
last year. 
 
• Sales figures provided by the PAGB show that wholesale purchases of PSE 
products by pharmacies declined by 24% from April 2010 to March 2011.  
 
The ACPO reported one incidence of an individual purchasing single packs of PSE 
products across a wide area for use in the small-scale manufacture of 
methylamphetamine. The lab was non-operational when found. There was no evidence 
that this one report was indicative of a trend. 
 
The number of registered methylamphetamine addicts remains small. The ACPO’s 
assessment, based on findings to date, is that there is low availability of 
methylamphetamine across the UK. 
 
 
Conclusions 
 
In July 2011, the CHM considered the above feedback from stakeholders and 
concluded that the regulatory measures implemented in 2009 and 2010 to manage the 
risk of misuse of OTC medicines containing PSE or EPH were continuing to be 
effective. The CHM recommended that:  
 
• the present levels of monitoring, education and awareness measures by 
pharmacists should be maintained 
 
                                                 
a The regulatory body for pharmacists, pharmacy technicians and pharmacy premises in the UK 
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• liaison with stakeholders including the Home Office, the Association of Chief 
Police Officers (ACPO) and the Serious Organised Crime Agency (SOCA) 
should continue 
 
• a Working Group should be established as necessary to review the situation if 
any new concerns arisea.  
 
• An update report should be considered by the CHM in 2012 
 
 
The CHM commended the pharmacy profession for their continued significant 
contribution to managing the risk of misuse of OTC medicines containing PSE or EPH. 
 
 
                                                 
a Please note that the majority of the members of the original 2007 Working Group are no longer 
members of the CHM 
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 1. INTRODUCTION 
(See glossary for explanation of medical terms) 
 
The Medicines and Healthcare products Regulatory Agency (MHRA) is the government 
agency responsible for regulating medicines and medical devices in the UK. We 
continually review the safety of all medicines in the UK and inform healthcare 
professionals and the public of the latest updates. The following report summarises the 
latest review of the impact of measures introduced to control potential misuse of 
medicines that contain pseudoephedrine (PSE)) or ephedrine (EPH), in the 
manufacture of the Class A controlled drug methylamphetamine. 
 
 
 
2. BACKGROUND 
 
PSE and EPH are nasal decongestants contained in many cough and cold medicines 
sold OTC in UK pharmacies. There has been increasing concern that PSE and EPH 
can be extracted relatively easily from over-the-counter (OTC) medicines and used in 
the illicit manufacture of methylamphetamine (colloquially known as 
‘methamphetamine’, ‘crystal meth’ or ‘ice’). Methylamphetamine was classified on 18 
January 2007 by the Home Office as a Class A controlled drug, based on the 
recommendation of the Advisory Council on the Misuse of Drugsa (ACMD).  
 
Because of this concern, a public consultation was carried out in March 2007 on 
minimising the risk of misuse of medicines containing PSE or EPH in the manufacture 
of methylamphetamine. In this consultation, the MHRA sought views on restricting the 
availability of these medicines by changing their legal status from pharmacy (P) to 
prescription-only medicines (POM), together with a restriction in their pack size.  
 
In July 2007, the Commission on Human Medicines (CHM; an independent body who 
give advice to government Ministers about the safety, quality, and efficacy of 
medicines) considered the responses to the consultation. They advised that the legal 
status of medicines containing (PSE) and ephedrine (EPH) should be reclassified from 
P to POM in July 2009, unless the risk of misuse of these OTC medicines in the illicit 
manufacture of methylamphetamine was contained. The CHM provided advice on pack 
size restrictions and other measures to control supply of OTC medicines containing 
PSE and EPH, and advised that a Working Group should be set up to advise on 
implementation of the measures (see press release and weblinked minutes). 
Accordingly, the CHM Working Group on PSE and EPH (Working Group) was 
established in September 2007 to advise the CHM on the implementation of measures 
that should be put in place to minimise the misuse of OTC medicines containing PSE 
or EPH in the illicit manufacture of methylamphetamine.  
 
Following CHM advice to restrict pack sizes of PSE and EPH, a further public 
consultation in October 2007 considered specific amendments to the Prescription Only 
Medicines Order 1997 (POM Order) to make the sale and supply of products 
containing more than 720 mg of PSE or 180 mg EPH prescription-only. This legislation 
(SI 2008/464) came into force on 1st April 2008, after which it became illegal to sell or 
supply: 
 
• any product that contains more than 720 mg PSE or 180 mg EPH without a 
prescription. 
• a combination of products that between them add up to more than 720 mg PSE 
or 180 mg EPH without a prescription 
                                                 
a An independent expert body that advises the government on drug-related issues in the UK 
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• a product that contains PSE and a product that contains EPH in one 
transaction  
 
Professional guidance was also issued by the Royal Pharmaceutical Society [RPS]), 
formerly known as the Royal Pharmaceutical Society of Great Britain (RPSGB), for 
PSE or EPH-containing products to be supplied personally by a pharmacist or a trained 
staff member under the supervision of a pharmacist (see section 3.1 below). 
 
In July 2009, and again in July 2010, the CHM considered the impact of measures 
which had been put in place to minimise the risk of misuse of PSE and EPH-containing 
products and recommended that: the existing levels of monitoring, education and 
awareness measures by pharmacists should be maintained; liaison with stakeholders 
including the Home Office (HO), Association of Chief Police Officers (ACPO) and the 
Serious Organised Crime Agency (SOCA) should continue; the Working Group should 
be reconstituted as necessary, and in any case to review the situation on a yearly 
basis.  
 
Two public assessment reports published in July 2009 and July 2010 giving full details 
of the measures and the CHM’s conclusions are available on our website: MHRA 
Public Assessment Report: Controlling the risk of misuse of medicines containing 
pseudoephedrine and ephedrine and MHRA Public Assessment Report: 
Pseudoephedrine and ephedrine: managing the risk of misuse of medicines – July 
2010 update. Articles on this issue were also published in the September 2009 and 
September 2010 editions of Drug Safety Update, the MHRA monthly bulletin for health 
professionals on the safety of medicines. 
 
 
 
3. UPDATE ON IMPLEMENTATION OF MEASURES 
 
In light of the CHM’s recommendations above, stakeholders have continued to take 
measures to help minimise the misuse of OTC medicines containing PSE or EPH in the 
illicit manufacture of methylamphetamine. Information provided recently is summarised 
below. 
 
3.1  Pharmacy supervision plus education and awareness initiatives 
 
The Working Group established close links with the RPS, the Pharmaceutical Society 
of Northern Ireland (PSNI) the National Pharmacy Association (NPA) the Company 
Chemists Association (CCA) and the Proprietary Association of Great Britain (PAGB). 
These organisations have provided updated information to the MHRA on the continuing 
measures to maintain awareness by the pharmacy profession of the indirect abuse 
potential of medicines containing PSE or EPH. 
 
The RPS is committed to supporting pharmacists in relation to the misuse of PSE or 
EPH and issues regular communications to members to ensure they maintain vigilance 
with these products. These include a ‘Look, Listen and Report your suspicions’ guide, 
and a specific section on PSE and EPH in the July 2011 edition of ‘Medicines, Ethics 
and Practice’. 
 
The PSNI has placed guidance on its website relating to PSE sales. Monitoring the 
website shows there is constant access of this information by either professionals or 
the public. The PSNI liaises with the Department of Health, Social Services and Public 
Safety (DHSSPS) and its pharmaceutical inspectorate, and there is no current 
evidence of any problem issues with the sale and supply of PSE-containing products in 
Northern Ireland. 
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The NPA continues to maintain and develop an awareness training resource for 
members to download from the NPA website. It is now available in various formats to 
suit the users, eg, group training or individual learner, and also for use with an MP3 
player. From June 2010 – June 2011, there were 2390 visits to the online training site. 
Pharmacists are encouraged to record staff training as part of an audit trail. The NPA 
reminds members at intervals to ensure that newly appointed staff are made aware of 
the current rules by means of superintendent email alerts, the NPA member magazine, 
and press releases. In a survey conducted in June 2011 of 410 members, 97% of 
members responded that they are aware of the rules regarding sales of PSE-containing 
products. Training packs will be sent to those members who responded that were not 
aware of these rules. The NPA are reassured by the high level of awareness, which 
remains unchanged from last year. 
 
The CCA continues to operate the MethGuard UK awareness training programme, 
although numbers completing the programme have decreased, possibly because the 
vast majority of members have now developed their own in-house resource, including 
several major high-street pharmacy stores. Companies report that awareness training 
on the rules regarding sales of products containing PSE or EPH is part of the standard 
training for all relevant staff (eg, medicines counter assistants) and new staff. Some 
companies provide refresher training prior to the autumn/winter cough and cold 
season, and audit compliance through different schemes (eg, a mystery shopper 
scheme). 
 
3.2  Pharmacy reporting of suspicions 
 
The ‘Look, Listen and Report your suspicions’ guide is available to members on the 
RPS website. The RPS inspectorate is now part of the GPhC. The GPhC are not aware 
of any cases of inappropriate sales of PSE or EPH products over the last year, and 
report that pharmacists are aware and alert to the potential abuse of products 
containing these medicines. 
 
3.3 Sales monitoring for evidence of use of over-the-counter medicines in the 
manufacture of methylamphetamine 
 
The PAGB provided wholesale figures for PSE, EPH and phenylephrine (PE) products. 
The figures show a decline in wholesale purchases by pharmacies for all three 
products, of 24%, 8% and 17%, respectively, during the financial year April 2010–
March 2011. The manufacturers of brand leader products have reported a reduction of 
up to 25% in sales of PSE-containing products, despite the high incidence of flu over 
the last year.  
 
3.4  Triggers for a review of the availability of pseudoephedrine or ephedrine 
over-the-counter medicines 
 
The CHM has previously agreed a number of factors which act as potential triggers for 
a review of the pharmacy/OTC availability of PSE or EPH-containing medicines. The 
ACPO, SOCA and the Home Office have provided updated information in these areas 
which is summarised below: 
 
The ACPO reported one incidence of an individual purchasing single packs of PSE 
products across a wide area, for use in the small-scale manufacture of 
methylamphetamine. The lab was non-operational when found.  
 
Another report from ACPO concerned a small-scale facility using PSE products from 
abroad which had been bought over the internet. The operator stated that ‘the amount 
of ephedrine contained in UK products was too small to make the process of extracting 
it worthwhile’. 
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Reports of suspicious requests for OTC PSE or EPH-containing medicines by 
pharmacists to RPSGB/SOCA are documented via the reporting system (the ‘Look, 
Listen and Report your suspicions’ guide). Over 2010 – 2011, there were four 
pharmacy suspicion reports of customers behaving suspiciously when attempting to 
purchase quantities of PSE or EPH. In the areas of these reports, reminders were 
issued to community pharmacies to alert them to the situation. Data from the last five 
years do not indicate a significant increase in the number of methylamphetamine users, 
and the numbers of registered methylamphetamine addicts remains smalla. 
 
There have been no other reports of concern from ACPO or SOCA regarding misuse of 
PSE or EPH products. Based on findings to date, the ACPO’s assessment is that there 
is low availability of methylamphetamine across the UK. 
 
Liaison with relevant stakeholders including ACPO, SOCA, and the GPhC Pharmacy 
inspectorate will continue to provide suitable information as it arises. Overall, SOCA 
and ACPO are aware of the potential dangers of misuse, but have indicated that 
currently there is no substantial evidence for misuse on a widespread basis. They 
consider that the current restrictions on OTC medicines containing PSE or EPH are 
sufficient to address the risk of potential misuse and abuse. 
 
 
 
4. INTERNATIONAL POSITION  
 
An update of available information on international measures to minimise the risk of 
misuse of PSE or EPH-containing medicines is provided below. 
 
USA 
There have been no changes in the marketing of PSE in the USA in recent years. It is 
sold OTC (behind-the-counter) unless individual state laws dictate otherwise; over the 
last year more states have introduced legislation that restricts PSE to prescription 
status.  
 
 
New Zealand  
Concerns in New Zealand about the use of PSE as a precursor for the manufacture of 
methamphetamine led to the reclassification of pseudoephedrine in 2003 as a Class C 
controlled drug (Schedule 3 of the Misuse of Drugs Act 1975). Most manufacturers of 
cough and cold medicines in New Zealand have reformulated their products so that 
they do not contain PSE or EPH; there are now only a limited range of available 
medicines remaining which contain these products. However there are continuing 
media reports of product seizures at the border. 
 
 
 
5. DISCUSSION 
 
The feedback from stakeholders is that the regulatory measures recommended by the 
CHM to help manage the risk of misuse of OTC medicines containing PSE or EPH are 
continuing to be implemented effectively. There was one incidence of an individual 
purchasing PSE products for use in the manufacture of methylamphetamine; however 
the scale of the operation was reassuringly small. There is no evidence from ACPO 
that this case is indicative of a trend which requires additional measures to control the 
misuse of PSE-containing products.  
                                                 
a Data from the  British Crime Survey 2009 – 2010 and the National Treatment Agency
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The pharmacy representative organisations are maintaining their support and 
encouragement of education and training by pharmacists and pharmacy staff, to 
ensure awareness of misuse of PSE and EPH and the links to methylamphetamine 
misuse. 
 
There have been four reports from pharmacies of suspicious requests for unusual 
quantities of OTC PSE and these were handled locally.  
 
The factors that would trigger a review of continued OTC PSE or EPH availability have 
been reviewed and there are no significant issues of concern.  
 
Other countries are also taking steps to better manage the risk of misuse of PSE and 
EPH products. 
 
 
 
6. RECOMMENDATIONS AND CONCLUSIONS  
 
After reviewing the updated information summarised in this report, the CHM agreed 
that the measures implemented in 2007 and reviewed yearly since then are continuing 
to control the supply of OTC products containing PSE or EPH. The CHM 
recommended that:  
 
• the present level of monitoring and the education and awareness measures by 
pharmacists should be maintained 
 
• liaison with stakeholders including the Home Office, ACPO and SOCA should 
continue 
 
• a Working Group should be established as necessary to review the situation if any 
new concerns arisea.  
 
• A further update report should be considered by the CHM in 2012. 
 
 
The CHM commended the pharmacy profession for their continued significant 
contribution to managing the risk of misuse of OTC medicines containing PSE or EPH. 
 
.
                                                 
a Please note that the majority of the members of the original 2007 Working Group are no longer 
members of the CHM 
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 7. GLOSSARY 
 
Class A controlled drugs 
In the UK, certain drugs are designated as controlled substances (ie, only certain 
designated persons may manufacture, supply and possess them) and are divided into 
three classes: A, B and C. Those categorised as Class A are considered to be the most 
likely to cause harm (see 
http://webarchive.nationalarchives.gov.uk/20100419081707/http:/drugs.homeoffice.gov
.uk/drugs-laws/misuse-of-drugs-act/ for more information) 
 
Clinical Audit 
A process performed by the UK’s National Health Service that seeks to improve patient 
care and outcomes by reviewing performance in the Service 
 
Decongestant 
A drug that helps to clear a blocked nose 
 
Ephedrine 
A drug that narrows blood vessels and widens airways, used mainly as a nasal 
decongestant 
 
Illicit 
Illegal 
 
Legislation 
A proposed law or group of laws 
 
Methylamphetamine 
A Class A controlled drug that is illegal to possess, supply or manufacture. It is a 
stimulant that causes feelings of exhilaration 
 
Misuse (of medicines) 
Using a drug for improper purposes (ie, not for treating a condition or disease)  
 
Over-the-counter 
Medicines that can be sold to a customer without a prescription 
 
Pharmacy (referring to medicine classification) 
Medicines that can only be sold to a customer by a trained pharmacist 
 
Phenylephrine 
A drug that narrows blood vessels, used mainly as a nasal decongestant 
 
Precursor (chemical) 
A chemical that is required in the process of making a drug, which becomes part of the 
end-product 
 
Prescription Only Medicine 
Medicines that can only be sold to a customer if they have a valid prescription from a 
doctor 
 
Pseudoephedrine 
A drug that narrows blood vessels, used as a nasal decongestant 
 
Public Consultation 
A process that seeks the public’s input on matters that affect them 
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Stakeholders 
A person, group, organisation or system which affects, or can be affected by, an 
organisation’s actions 
 
Stimulant 
A substance that causes increased activity in the body, particularly in the nervous 
system, and the heart and circulatory system 
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